BMY Jan 2026 30.000 call
| Previous close | 13.70 |
| Open | 12.95 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 30.00 |
| Expiry date | 2026-01-16 |
| Day's range | 12.95 - 14.19 |
| Contract range | N/A |
| Volume | |
| Open interest | 214 |
Business WireBristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
PRINCETON, N.J., May 23, 2024--Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
ZacksBristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
